Achillion's Elvucitabine Shows Positive Preliminary Results
Posted on: Wednesday, 17 October 2007, 15:00 CDT
Achillion Pharmaceuticals said that preliminary 12-week results from an ongoing Phase II trial studying elvucitabine in patients infected with wild-type HIV showed potent antiviral activity similar to GlaxoSmithKline's Epivir.
Elvucitabine is an L-cytosine nucleoside analog reverse transcriptase inhibitor that has previously demonstrated potent antiviral activity against HIV, including strains resistant to other NRTIs.
The objectives of the study include demonstration of the safety, tolerability and antiviral activity with a 10mg dose of elvucitabine, as compared to Epivir (lamivudine) in a standard triple-combination regimen. The results at 12 weeks demonstrated potent anti-viral activity similar to lamivudine, Achillion said.
Michael Kishbauch, president and CEO of Achillion, commented: "As we anticipated, the end of 2007 is going to be an important period for Achillion, as we prepare to report additional data from our Phase II program with elvucitabine.
"The majority of the patients in this ongoing study have already completed 24-weeks of treatment, and we anticipate reporting topline 24-week data by early next year."
Source: Datamonitor
Related Articles
- Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting
- Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
- Data From Achillion's Antibacterial and HIV Programs Presented At the 2008 ICAAC/IDSA Joint Meeting
- Achillion Appoints Nicholas Simon to Board of Directors
- Siga Files Application for Emergency Use of Antiviral Drug
- Pharmasset Says Hepatitis C Drug Meets Trial Goals
- R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
- Antiviral Therapeutics: Pipelines and Competitive Dynamics Report Surveys the 5 Major Viral Disease Categories and Their Sub-Indications
- Clinical Issues and Research in Respiratory Failure From Severe Acute Respiratory Syndrome
- IL-7 is a Potent and Proviral Strain-Specific Inducer of Latent HIV- 1 Cellular Reservoirs of Infected Individuals on Virally Suppressive HAART
 |
 |
User Comments (0)
RSS Feeds